ArticlePharmacoEconomics2015

Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.

Katharina Schremser et al.PubMed ↗Publisher ↗

No numbers read from the abstract.